Ondansetron for the control of dacarbazine-induced emesis

European Journal of Cancer

Volumn 31, Issue 10, 1995, Pages 1720-1721

  Campora, E ^a   Chiara, S ^a   Aschele, C ^a  

^a UNIVERSITY OF GENOA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DACARBAZINE; FOTEMUSTINE; ONDANSETRON;

ADULT; AGED; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONSTIPATION; HEADACHE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LETTER; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; VOMITING;

AGED; ANTIEMETICS; ANTINEOPLASTIC AGENTS; DACARBAZINE; HUMAN; MIDDLE AGE; NAUSEA; ONDANSETRON; VOMITING;

EID: 0028829237     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/0959-8049(95)00313-8     Document Type: Letter

References (6)

1. Comparison of the 5-hydroxy-tryptamine (serotonin) antagonist ondansetron (GR 38032F) with high-dose metoclopramide in the control of cisplatin-induced emesis
2. Prevention of cisplatin-induced emesis: a double-blind mullicentre randomized cross-over study comparing ondansetron and ondansetron plus dexamethasone
3. Neuropharmacology of chemotherapy induced emesis
4. High-dose metoclopramide: control of dacarbazine-induced emesis in a preliminary trial
5. Antiemetic activity of highdose metoclopramide combined with methylprednisolone versus metoclopramide alone in dacarbazine-treated cancer patients
6. Dacarbazine and fotemustine in advanced colorectal cancer